Home Clinical development Phase I

Phase I

Phase I

Breakthrough Therapy Designation for Venetoclax + Azacitidine in Myelodysplastic Syndromes

Editorial Team - July 20, 2021

Valemetostat Promises Durable Tumor Response in Peripheral T-Cell Lymphoma and T-Cell Leukemia

Advancing Treatment Options with Immunotherapies in Non-Hodgkin’s Lymphoma

Loncastuximab Tesirine Offers a Therapeutic Option for Heavily Pretreated Patients with r/r DLBCL

Thoughtful young women suffering from ovarian cancer.

First Patient Dosed in Phase III Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer

Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Combination of SLC-391 + Pembrolizumab Enters Clinical Trial Advanced NSCLC

Peter Hofland, Ph.D - March 31, 2021

Phase I Study Shows Positive Interim Results of TRPH-222 in Patients...

Peter Hofland, Ph.D - December 7, 2020

NIH Starts Clinical Trial with ONC206, a Next-Generation Imipridone

Editorial Team - October 29, 2020

Doctor discussing treatment options with a patient.

Investigator-Initiated Study Supports Potential of VS-6766 as Treatment for RAS Mutant...

Editorial Team - October 29, 2020

$Inhibition of HDAC + mTOR May Improve Outcomes in Relapsed/Refractory Hodgkin Lymphoma$

Inhibition of HDAC + mTOR May Improve Outcomes in Relapsed/Refractory Hodgkin...

Editorial Team - October 14, 2020

ESMO 2020: First-in-class MK-4830 Antibody Targeting ILT4 Shows Promising Preliminary...

Editorial Team - September 20, 2020

ESMO 2020: Sotorasib Active in Patients with KRAS p.G12C Mutation –...

Editorial Team - September 20, 2020

LATEST NEWS

Regular Blood Monitoring and a Tailored Treatment Approach in Mycosis Fungoides and Sézary Syndrome

Editorial Team - July 22, 2021

The National Cancer Act at 50: The Greatest Scientific Discovery Effort in History.

Peter Hofland, Ph.D - July 21, 2021

In States that Expanded Medicaid Cancer Mortality Rates Declined More Steeply

Editorial Team - July 21, 2021

Breakthrough Therapy Designation for Venetoclax + Azacitidine in Myelodysplastic Syndromes

Editorial Team - July 20, 2021

Patients with Relapsed/Refractory AML may Benefit from Treatment with Ficlatuzumab + Chemotherapy

Editorial Team - July 18, 2021

Press Releases | Cancer

Local Breast Cancer Patients Experiencing Faster Recovery With PRMA’s... July 23, 2021
PRMA’s ERAS Protocol significantly decreases patient’s postoperative pain after breast reconstruction.(PRWeb July 23, 2021)Read the full story at https://www.prweb.com/releases/local_breast_cancer_patients_experiencing_faster_recovery_with_prmas_new_recovery_protocol/prweb18088964.htm
Mount Sinai Researchers Develop Novel Therapy That Could Be Effective... July 23, 2021
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer...(PRWeb July 23, 2021)Read the full story at https://www.prweb.com/releases/mount_sinai_researchers_develop_novel_therapy_that_could_be_effective_in_many_cancers/prweb18083920.htm
Deep Bio Announces Research Collaboration with a Major Cancer... July 22, 2021
Deep Bio renews Research Collaboration Agreement with Dana-Farber Cancer Institute(PRWeb July 22, 2021)Read the full story at https://www.prweb.com/releases/deep_bio_announces_research_collaboration_with_a_major_cancer_institute/prweb18081063.htm